SCM
FULC icon

Suvretta Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Suvretta Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.3M Hold
6,561,111
– – 1.29% 31
2025
Q4 		$74.2M Buy
6,561,111
+1,180,111
+22% +$12M 1.52% 29
2025
Q3 		$49.5M Buy
5,381,000
+298,100
+6% +$2.16M 1.27% 32
2025
Q2 		$35M Buy
5,082,900
+15,506
+0.3% +$82.9K 1.05% 33
2025
Q1 		$14.6M Buy
5,067,394
+1,728,928
+52% +$6.35M 0.54% 49
2024
Q4 		$15.7M Buy
3,338,466
+2,155,675
+182% +$7.95M 0.53% 49
2024
Q3 		$4.22M Sell
1,182,791
-1,358,255
-53% -$10.1M 0.14% 66
2024
Q2 		$15.8M Sell
2,541,046
-307,440
-11% -$2.33M 0.58% 43
2024
Q1 		$26.9M Sell
2,848,486
-2,670,395
-48% -$23.8M 1% 34
2023
Q4 		$37.3M Sell
5,518,881
-200,000
-3% -$887K 1.68% 21
2023
Q3 		$25.4M Hold
5,718,881
– – 1.37% 24
2023
Q2 		$18.9M Buy
5,718,881
+541,171
+10% +$1.59M 1.01% 35
2023
Q1 		$14.8M Buy
5,177,710
+902,907
+21% +$8.09M 0.62% 45
2022
Q4 		$31.1M Buy
4,274,803
+746,803
+21% +$4.87M 1.31% 31
2022
Q3 		$28.5M Buy
3,528,000
+172,376
+5% +$1.23M 1.19% 32
2022
Q2 		$16.4M Buy
3,355,624
+742,212
+28% +$7.25M 0.63% 49
2022
Q1 		$61.8M Buy
2,613,412
+237,841
+10% +$3.37M 1.89% 23
2021
Q4 		$42M Buy
2,375,571
+433,602
+22% +$8.59M 0.81% 35
2021
Q3 		$54.8M Buy
1,941,969
+314,525
+19% +$5.96M 0.92% 34
2021
Q2 		$17.1M Buy
1,627,444
+101,559
+7% +$1.03M 0.26% 65
2021
Q1 		$18M Buy
+1,525,885
New +$18.9M 0.27% 61

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Suvretta Capital Management's FULC Position: Q1 2026 in Review

Suvretta Capital Management held its Fulcrum Therapeutics (FULC) position steady in Q1 2026 at 6,561,111 shares worth $50.3M. The position accounts for 1.29% of the portfolio, ranked #31.

Suvretta Capital Management first reported a position in FULC in Q1 2021 and has held it in 21 quarters since. The position peaked at $74.2M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Suvretta Capital Management held 6,561,111 shares of Fulcrum Therapeutics worth $50.3M as of Q1 2026.
  • Suvretta Capital Management left its Fulcrum Therapeutics share count unchanged in Q1 2026.
  • Fulcrum Therapeutics made up 1.29% of Suvretta Capital Management's portfolio in Q1 2026, its #31 holding.
  • Suvretta Capital Management first reported a position in Fulcrum Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Suvretta Capital Management's Fulcrum Therapeutics position peaked at $74.2M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.